Alejandro Macchia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4992809/publications.pdf

Version: 2024-02-01

53 papers

2,687 citations

249298 26 h-index 51 g-index

62 all docs

62 docs citations

times ranked

62

4106 citing authors

#	Article	IF	CITATIONS
1	Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials. The Lancet Regional Health Americas, 2022, 9, 100196.	1.5	5
2	Evaluation of the first level of care for tuberculosis control in Buenos Aires, Argentina. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2021, 45, 1.	0.6	2
3	Use of alternative care sites during the COVID-19 pandemic in the city of Buenos Aires, Argentina. Public Health, 2021, 194, 14-16.	1.4	3
4	COVID-19 among the inhabitants of the slums in the city of Buenos Aires: a population-based study. BMJ Open, 2021, 11, e044592.	0.8	12
5	Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country. JAMA Network Open, 2021, 4, e2130800.	2.8	40
6	Health as a Human Right: A Fake News in a Post-human World?. Development, 2020, 63, 270-276.	0.5	1
7	An analysis of death trends in Argentina, 1990-2017, with emphasis on the effects of economic crises. Journal of Global Health, 2020, 10, .	1.2	2
8	Cardiovascular and other risk factors among people who live in slums in Buenos Aires, Argentina. Public Health, 2019, 170, 38-44.	1.4	3
9	The challenges of estimations: a Southern world view. European Heart Journal Supplements, 2018, 20, C23-C24.	0.0	O
10	Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis. PLoS ONE, 2016, 11, e0148756.	1.1	18
11	Circulating cardiac biomarkers and postoperative atrial fibrillation in the <scp>OPERA</scp> trial. European Journal of Clinical Investigation, 2015, 45, 170-178.	1.7	23
12	On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate. European Journal of Clinical Pharmacology, 2015, 71, 449-459.	0.8	1
13	Macitentan and Pulmonary Arterial Hypertension. New England Journal of Medicine, 2014, 370, 81-83.	13.9	11
14	Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 463-468.	1.2	119
15	Reply. Journal of the American College of Cardiology, 2013, 61, 1552-1553.	1.2	1
16	Reply. Journal of the American College of Cardiology, 2013, 62, 84-85.	1.2	0
17	Nâ€3 Polyunsaturated Fatty Acids to Prevent Atrial Fibrillation: Updated Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2013, 2, e005033.	1.6	89
18	Plasma Phospholipid Omegaâ€3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. Journal of the American Heart Association, 2013, 2, e000397.	1.6	24

#	Article	IF	CITATIONS
19	Exploratory Analysis on the Use of Statins with or without n-3 PUFA and Major Events in Patients Discharged for Acute Myocardial Infarction: An Observational Retrospective Study. PLoS ONE, 2013, 8, e62772.	1.1	18
20	Fish Oil and Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2012, 308, 2001.	3.8	201
21	Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. European Heart Journal, 2012, 33, 515-522.	1.0	16
22	Previous prescription of \hat{l}^2 -blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis*. Critical Care Medicine, 2012, 40, 2768-2772.	0.4	86
23	Unrecognised ventricular dysfunction in COPD. European Respiratory Journal, 2012, 39, 51-58.	3.1	119
24	Statins but Not Aspirin Reduce Thrombotic Risk Assessed by Thrombin Generation in Diabetic Patients without Cardiovascular Events: The RATIONAL Trial. PLoS ONE, 2012, 7, e32894.	1.1	25
25	Educational inequalities in obesity, abdominal obesity, and metabolic syndrome in seven Latin American cities: the CARMELA Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 550-556.	3.1	45
26	The ω-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trialâ€"rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	1.2	31
27	Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2011, 17, 850-859.	0.7	64
28	Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension: Where Do We Go from Here?. Reviews on Recent Clinical Trials, 2011, 6, 228-234.	0.4	6
29	Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. Journal of Hypertension, 2010, 28, 24-34.	0.3	80
30	DIAL Trial Not Included in a Review of Health Failure Management Programs. Journal of the American College of Cardiology, 2010, 56, 159-160.	1.2	0
31	Long-Term Results After a Telephone Intervention in Chronic Heart Failure. Journal of the American College of Cardiology, 2010, 56, 372-378.	1.2	126
32	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal, 2010, 159, 245-257.	1.2	106
33	Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. European Journal of Clinical Pharmacology, 2009, 65, 1131-1138.	0.8	25
34	High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. Diabetic Medicine, 2009, 26, 864-871.	1.2	62
35	The rationale and design of the FORωARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal, 2009, 157, 423-427.	1.2	29
36	Anemia and chronic heart failure: from pathophysiologic mechanisms to clinical trial designs. Expert Review of Cardiovascular Therapy, 2009, 7, 139-145.	0.6	1

#	Article	IF	Citations
37	Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. European Journal of Clinical Pharmacology, 2008, 64, 627-634.	0.8	49
38	CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. American Journal of Medicine, 2008, 121, 58-65.	0.6	275
39	Depression worsens outcomes in elderly patients with heart failure: An analysis of 48,117 patients in a community setting. European Journal of Heart Failure, 2008, 10, 714-721.	2.9	46
40	The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. European Journal of Heart Failure, 2007, 9, 942-948.	2.9	90
41	A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal, 2007, 153, 1037-1047.	1.2	200
42	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)–Prevenzione scoring. American Heart Journal, 2006, 151, 754.e7-754.e17.	1.2	26
43	Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine, 2006, 7, 347-350.	0.6	96
44	Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. European Heart Journal, 2006, 27, 2217-2223.	1.0	60
45	Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology, 2005, 206, 117-128.	1.0	34
46	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure, 2005, 7, 904-909.	2.9	101
47	Determinants of Late-Onset Heart Failure in Myocardial Infarction Survivors: GISSI Prevenzione Trial Results. Revista Espanola De Cardiologia (English Ed), 2005, 58, 1266-1272.	0.4	0
48	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 277-283.	1.2	147
49	Assessment of survival benefit after lung transplantation by patient diagnosis. Journal of Heart and Lung Transplantation, 2003, 22, 705.	0.3	0
50	Anti-human skeletal muscle glycolipid antibodies in unstable angina. American Heart Journal, 2001, 141, 780-783.	1.2	0
51	Myocardial revascularization with radial and mammary arteries: initial and mid-term results. Annals of Thoracic Surgery, 2000, 70, 1378-1383.	0.7	27
52	Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non–Q-wave acute myocardial infarction. American Journal of Cardiology, 1999, 83, 515-518.	0.7	41
53	Total myocardial revascularization with arterial conduits: Radial artery combined with internal thoracic arteries. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 911-916.	0.4	72